You have 6 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

camostat mesylate

Showing 26 - 50 of 514
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022

SARS-CoV Infection, COVID-19 Trial (Mitoquinone/mitoquinol mesylate, Placebo)

Not yet recruiting
  • SARS-CoV Infection
  • COVID-19
  • Mitoquinone/mitoquinol mesylate
  • Placebo
  • (no location specified)
Jun 1, 2023

Camrelizumab Combined With Apatinib Mesylate in Unresectable

Recruiting
  • Hepatocellular Carcinoma
    • Fuzhou, Fujian, China
      Mengchao Hepatobiliary Hospital, Fujian Medical University
    Aug 24, 2022

    Covid19 Trial in Pleasanton, Stanford (Camostat, Placebo)

    Active, not recruiting
    • Covid19
    • Pleasanton, California
    • +1 more
    May 24, 2022

    Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

    Recruiting
    • Diffuse Large B Cell Lymphoma，DLBCL
    • PM 8.4 mg/m2
    • PM 11.2 mg/m2
    • Chengdu, Sichuan, China
      West China Hospital Sichuan University
    Jan 15, 2023

    Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

    Recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Nanjing, Jiangsu, China
      Jiangsu Province Hospital
    Nov 6, 2022

    Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

    Active, not recruiting
    • Metastatic Castration Resistant Prostate Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 23, 2022

    Healthy Volunteers Trial in Changsha (TY-9591 Tablets under Fasted Condition - Arm1, Osimertinib Mesylate Tablets under Fasted

    Completed
    • Healthy Volunteers
    • TY-9591 Tablets under Fasted Condition - Arm1
    • +5 more
    • Changsha, Hunan, China
      Hunan Provincial Tumor Hospital
    Dec 6, 2022

    Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral

    Recruiting
    • Locally Advanced Renal Pelvis Urothelial Carcinoma
    • +20 more
    • Duarte, California
    • +16 more
    Aug 10, 2022

    HIV-1-infection Trial in United States (CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg)

    Not yet recruiting
    • HIV-1-infection
    • CVC 150 mg
    • +3 more
    • Los Angeles, California
    • +16 more
    Nov 22, 2022

    Critical Illness, Anticoagulation Trial (Nafamostat Mesylate, Unfractionated Heparin)

    Not yet recruiting
    • Critical Illness
    • Anticoagulation
    • Nafamostat Mesylate
    • Unfractionated Heparin
    • (no location specified)
    Sep 23, 2022

    Liposarcoma, Malignant Abdominal Tumor, Malignant Retroperitoneal Tumor Trial in Portland (drug, radiation, other, procedure)

    Recruiting
    • Liposarcoma
    • +5 more
    • Eribulin Mesylate
    • +5 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Oct 17, 2022

    Metastatic Malignant Tumor in the Adult Brain, Primary Brain Tumor Trial in Duarte (procedure, drug, other)

    Active, not recruiting
    • Metastatic Malignant Neoplasm in the Adult Brain
    • Primary Brain Tumor
    • Therapeutic Conventional Surgery
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    Mar 16, 2022

    Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium

    Completed
    • Head and Neck Squamous Cell Carcinoma
    • Apatinib Mesylate Tablets
    • Tegafur Gimeracil Oteracil Potassium Capsules
    • Shanghai, Shanghai, China
      Shanghai ninth people's hospital
    Jul 20, 2022

    Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 15, 2022

    Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative Trial in Duarte, Rancho Cucamonga, South Pasadena

    Completed
    Has Results
    • Estrogen Receptor Negative
    • +4 more
    • Duarte, California
    • +2 more
    Jun 6, 2022

    Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma Trial in United States (Eribulin Mesylate, Laboratory

    Suspended
    • Breast Adenocarcinoma
    • +4 more
    • Eribulin Mesylate
    • +3 more
    • Scottsdale, Arizona
    • +38 more
    May 25, 2022

    Gastric Cancer Trial in Seoul (Apatinib mesylate)

    Completed
    • Gastric Cancer
    • Apatinib mesylate
    • Seoul, Songpa-gu, Korea, Republic of
      Asan medical center
    Jul 20, 2022

    Puberty; Precocious, Central Trial (Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide)

    Not yet recruiting
    • Puberty; Precocious, Central
    • Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
    • (no location specified)
    Aug 5, 2022

    CML Trial in Tempe (Imatinib Mesylate, IkT-001Pro)

    Recruiting
    • CML
    • Tempe, Arizona
      Celerion
    Nov 21, 2022

    Solid Tumor Trial in Henan (Camrelizumab combined with apatinib mesylate)

    Recruiting
    • Solid Tumor
    • Camrelizumab combined with apatinib mesylate
    • Henan, China
      Henan Tumor Hospital
    May 15, 2022

    Dilated Cardiomyopathy Trial (MitoQ Compound, Placebo)

    Recruiting
    • Dilated Cardiomyopathy
    • MitoQ Compound
    • Placebo
    • London, United Kingdom
      Royal Brompton Hospital
    Sep 16, 2022

    Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma Trial in Columbus (Lenvatinib Mesylate,

    Completed
    • Fallopian Tube Carcinoma
    • +3 more
    • Lenvatinib Mesylate
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 5, 2022

    Esophageal Tumors Trial (Apatinib, The chemotherapeutic drug chosen by the investigator.)

    Withdrawn
    • Esophageal Neoplasms
    • Apatinib
    • The chemotherapeutic drug chosen by the investigator.
    • (no location specified)
    Apr 11, 2022

    Leukemia Trial in Italy (drug, genetic, other)

    Completed
    • Leukemia
    • imatinib mesylate
    • +8 more
    • Rionero in Vulture, Potenza, Italy
    • +36 more
    Jan 3, 2022